What does this research mean for the field?

Q: What does this research mean for the field?

The FDA's 1998 regulatory action, which included a boxed warning and a 'Dear Health Care Professional' letter, had no material effect on reducing the contraindicated use of cisapride. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

December 20, 2000JAMA

Contraindicated Use of Cisapride

View Full Paper

Ask AI

Bookmark

Why the study?

Does the FDA's 1998 regulatory action reduce the contraindicated use of cisapride in patients prescribed the drug?

Population

Patients with at least 180 days of prior enrollment in 2 managed care organizations or a state Medicaid…

Comparison

FDA's 1998 regulatory action regarding… vs 1-year period before the regulatory action

Design

Cohort

Follow-up

1 year

Authors

WSWalter SmalleyVanderbilt University DSDeborah ShatinUniversity of Minnesota DWDiane K. WysowskiUnited States Food and Drug Administration

Discussion

Member takes

Implication

Minimal impact after warnings suggests regulatory letters alone insufficient; challenges assumptions on FDA communication efficacy and leaves open need for stronger interventions.

Structured PICO

Does the FDA's 1998 regulatory action reduce the contraindicated use of cisapride in patients prescribed the drug?

Population

Patients with at least 180 days of prior enrollment in 2 managed care organizations or a state Medicaid program who were prescribed cisapride at least once in the 1-year period before (n = 24,840) or after (n = 22,459) regulatory action.

Intervention

FDA's 1998 regulatory action (additions to boxed warning and 'Dear Health Care Professional' letter) regarding contraindicated use of cisapride

Comparator

1-year period before the regulatory action (July 1997-June 1998)

Outcome

Proportion of cisapride users in each period for whom cisapride use was contraindicated by the product labelsafety

The FDA's 1998 regulatory action (boxed warnings and letters) had no material effect on reducing the contraindicated use of cisapride, highlighting the need for more effective drug safety communication.

Cite This Study

Smalley et al. (2000) studied this question.

synapsesocial.com/papers/6a1c0799ea84844e355f577a https://doi.org/10.1001/jama.284.23.3036

View Full Paper

Ask AI

Bookmark

Implication

Minimal impact after warnings suggests regulatory letters alone insufficient; challenges assumptions on FDA communication efficacy and leaves open need for stronger interventions.

Contraindicated Use of Cisapride

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Contraindicated Use of Cisapride

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider